PHG Foundation asks how MHRA's refreshed rare disease framework will reach patients

A new analysis from PHG Foundation (University of Cambridge) examines whether the MHRA's updated Rare Disease Therapies Regulatory Framework will translate regulatory approvals into real-world patient access in the UK.

Published · AI-drafted summary based on 1 public source
Illustration for rare disease story
Illustrative image — not from the source article.
Share

PHG Foundation, the health genomics policy unit based at the University of Cambridge, has published a blog analysis asking how the MHRA's refreshed Rare Disease Therapies Regulatory Framework can ensure that approvals for rare disease therapies result in timely patient access, rather than stalling at reimbursement or commissioning stages.

The piece situates the question within longstanding concerns about the gap between regulatory approval and NHS availability for orphan and ultra-orphan medicines. It notes that regulatory flexibility — such as conditional authorisations, adaptive licensing, and rolling review — can accelerate access to promising therapies, but that these mechanisms function poorly if health technology assessment bodies, payers, and commissioners are not aligned with the revised framework from the outset.

The analysis does not evaluate specific drugs or recommend particular interventions, but it highlights structural questions about how evidence requirements at approval stage interact with NICE appraisal criteria and NHS England commissioning decisions. It also raises the question of whether the refreshed framework adequately addresses the particular challenges of gene and cell therapies, where long-term outcomes data are inherently limited at the point of initial authorisation.

The blog is a policy commentary rather than a peer-reviewed study, and reflects the authors' current view on a framework that is still being developed. It is relevant reading for anyone following UK rare disease policy, genomic medicine implementation, or the regulation of advanced therapy medicinal products.

Plain-language version

For patients, families, and general readers. Educational only — not medical advice.

The MHRA is the UK body that decides whether medicines are safe and effective enough to be made available. It has updated its rules specifically for medicines that treat rare diseases — conditions that affect only a small number of people.

Researchers at PHG Foundation, based at the University of Cambridge, have published a commentary asking an important follow-up question: once a rare disease medicine is approved by the MHRA, how do we make sure patients can actually get it on the NHS? Regulatory approval and NHS availability are separate steps, and there have often been long delays between the two.

The commentary does not name specific medicines or tell patients what to do. It focuses on how UK policymakers could design better systems so that approvals translate into access, particularly for newer types of treatment such as gene therapies.

This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.

Sources

Read the original reporting — these are the public sources this summary draws from.

  1. Primary source PHG Foundation (University of Cambridge) · 2026-11-04
    Refreshing the rare disease therapies regulatory framework in the UK

Tags

rare-disease regulatory-policy mhra gene-therapy uk-policy patient-access atmp phg-foundation
Share

About Genetic Current

Educational summaries of public genetics news

Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.

Join the Evagene Alpha Waiting List